

Special Issue

Class 2 Tumor Suppressor Gene Pathways for Therapeutic Applications in Hard-to-Treat Cancers

Message from the Guest Editor

Hard-to-treat (HTT) cancers are a group of malignant tumors that are difficult to treat with conventional cancer treatments such as surgery, chemotherapy or radiotherapy. These cancers are typically more advanced or aggressive and are more likely to recur after treatment, resulting in poor prognosis. Examples of HTT cancers are pancreatic cancer, liver cancer, ovarian cancer, brain tumors, esophageal cancer and some types of blood cancer, such as multiple myeloma. This Special Issue will investigate to what extent the challenging treatment of HTT tumors could be complemented by epigenetic cancer therapies in the future. The focus will be on new approaches resulting from the understanding of epigenetic signaling pathways in the cancer cell. Of particular relevance here are class 2 tumor suppressor genes, which are silenced in tumors at the level of promoter DNA methylation. The Special Issue is intended to contribute to finding new ideas and starting points for the epigenetic therapy of HTT cancers. A first concept for this strategy has already been published by the recently: <https://www.mdpi.com/2072-6694/14/18/4386>.

Guest Editor

Prof. Dr. Edgar Dahl

Institute of Pathology, Medical Faculty, RWTH Aachen University, D-52074 Aachen, Germany

Deadline for manuscript submissions

30 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/si/172644](https://www.mdpi.com/si/172644)

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://www.mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)